Among causes of deaths, cancer is a major one responsible for mortality of some 6 million humans each year. Simultaneously, approximately 10 million new cases of cancer diseases are diagnosed yearly . There are no doubts then that cancer is one of the main targets in the search for new, reliable and efficient disease biomarkers that can be used in clinical practice to provide a real improvement of diagnosis and monitoring of therapy.
Currently, due to exceptional development in instrumental and bioinformatics technologies, the most attractive approaches to biomarker discovery from the scientific point of view are based on -omics. Since the 1990s, genomics, transcriptomics, proteomics and more recently metabolomics, have become the ‘gold standards‘ in advanced preclinical and clinical research.